Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis

Inclusion Criteria: * Female 18-65 years * Informed Consent * Clinical diagnosis of fluconazole-resistant VVC * Negative pregnancy test * Vaginal pH ≤ 4.5 Exclusion Criteria: * Intolerance or hypersensitivity to any amphotericin B (AMB) product or to azole antifungal drugs * Receiving antifungal therapy unrelated to VVC or has evidence of systemic fungal infections requiring antifungal therapy * Received antifungal treatment for VVC within past 10 days except fluconazole, subjects must discontinue fluconazole after informed consent * Has another cause or suspected cause of vulvovaginitis * Has active HPV * Has other urogenital infection * Has other vaginal or vulvar condition that would confound interpretation of clinical response * Has significant laboratory abnormality at screening * Has Type I diabetes, use of insulin, HbA1c\>10 * Exposure to any investigational product within 30 days of screening * Has other condition that would interfere with subject ability to provide informed consent or put subject at undue risk